

FRASER HEALTH
SURREY HEMATOLOGY
R

Jim Pattison Outpatient Care and Surgery Centre, Surrey Memorial Hospital
9750 140th Street, Surrey BC, V3T0G9
(p) 604-582-4550 Ext. 764191 (f) 604-528-5441

2021-Dec-06

Patient: Mr. Shaun MULLDOON
PHN:
Birthdate: [REDACTED]

To whom it may concern,

Please strongly consider Mr. Shaun Mulldoon for a COVID-19 vaccine medical deferral. He received his first non-replicating viral vector (AstraZeneca ChadOx1-S) COVID vaccination on April 22, 2021. Following this, he developed a complicated, life-threatening course with confirmed vaccine-induced thrombocytic thrombocytopenia (VITT) with a resultant pulmonary embolism and extensive intraabdominal thrombosis. This resulted in extensive ischemic bowel requiring extensive resection of his small bowel with a resultant ileostomy. He has required multiple IVIG infusions, a prolonged steroid course and is maintained on anticoagulation. His most recent PF4-ELISA antibodies remain positive 6 months after his VITT diagnosis in late November 2021. His serotonin release assay is also still positive for VITT PF4 antibodies.

As his hematologist, I fully support vaccine deferral in his case. Although the current deferral recommendations do not include patients with VITT/TTS as mRNA is recommended for these individuals, the exact safety of mRNA vaccinations in these individuals especially with persistently positive VITT PF4 antibodies is not fully known. Moreover, there has been a confirmed case of VITT/TTS following the Moderna mRNA vaccine (Swathi Sangli et al. Thrombosis With Thrombocytopenia After the Messenger RNA-1273 Vaccine. Ann Intern Med.2021;174:1480-1482. doi:10.7326/L21-0244), further supporting the consideration for deferral in Mr. Mulldoon especially with his ongoing positive antibodies.

Please do not hesitate to contact me if you have any questions or concerns.

Sincerely,



Electronically Reviewed to Expedite Delivery